Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Ambrose

Showing results (231-240 of 250) with videos related to

Pageof 25
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2018
Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant TuberculosisDevyani Deshpande, Jotam G Pasipanodya, Stellah G Mpagama, et al.
Antimicrobial Agents and Chemotherapy|November 5, 2014
Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infectionsSujata M Bhavnani, Jeffrey P Hammel, Scott A Van Wart, et al.
Antimicrobial Agents and Chemotherapy|September 28, 2023
Impact of antibiotic pharmacokinetics in urine on recurrent bacteriuria following treatment of complicated urinary tract infectionsDavid Melnick, Angela K Talley, Vipul K Gupta, et al.
Antimicrobial Agents and Chemotherapy|May 15, 2013
Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studiesC R Rayner, C C Bulik, M A Kamal, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 8, 2022
4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse Model of Osteogenesis ImperfectaIvan Duran, Jennifer Zieba, Fabiana Csukasi, et al.
Open Forum Infectious Diseases|November 28, 2025
Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and <i>Pseudomonas aeruginosa</i>: Brief SummarySujata M Bhavnani, Jeffrey P Hammel, Nikolas J Onufrak, et al.
Antimicrobial Agents and Chemotherapy|May 1, 2013
Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection modelBrian VanScoy, Rodrigo E Mendes, Anthony M Nicasio, et al.
Open Forum Infectious Diseases|November 28, 2025
Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and <i>Pseudomonas aeruginosa</i>Sujata M Bhavnani, Jeffrey P Hammel, Nikolas J Onufrak, et al.
Antimicrobial Agents and Chemotherapy|January 21, 2016
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection ModelAnthony M Nicasio, Brian D VanScoy, Rodrigo E Mendes, et al.
Antimicrobial Agents and Chemotherapy|March 22, 2023
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzaeSujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, et al.
Pageof 25

Showing results (231-240 of 250) with videos related to

Sort By:
Pageof 25
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2018
Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant TuberculosisDevyani Deshpande, Jotam G Pasipanodya, Stellah G Mpagama, et al.
Antimicrobial Agents and Chemotherapy|November 5, 2014
Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infectionsSujata M Bhavnani, Jeffrey P Hammel, Scott A Van Wart, et al.
Antimicrobial Agents and Chemotherapy|September 28, 2023
Impact of antibiotic pharmacokinetics in urine on recurrent bacteriuria following treatment of complicated urinary tract infectionsDavid Melnick, Angela K Talley, Vipul K Gupta, et al.
Antimicrobial Agents and Chemotherapy|May 15, 2013
Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studiesC R Rayner, C C Bulik, M A Kamal, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 8, 2022
4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse Model of Osteogenesis ImperfectaIvan Duran, Jennifer Zieba, Fabiana Csukasi, et al.
Open Forum Infectious Diseases|November 28, 2025
Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and <i>Pseudomonas aeruginosa</i>: Brief SummarySujata M Bhavnani, Jeffrey P Hammel, Nikolas J Onufrak, et al.
Antimicrobial Agents and Chemotherapy|May 1, 2013
Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection modelBrian VanScoy, Rodrigo E Mendes, Anthony M Nicasio, et al.
Open Forum Infectious Diseases|November 28, 2025
Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and <i>Pseudomonas aeruginosa</i>Sujata M Bhavnani, Jeffrey P Hammel, Nikolas J Onufrak, et al.
Antimicrobial Agents and Chemotherapy|January 21, 2016
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection ModelAnthony M Nicasio, Brian D VanScoy, Rodrigo E Mendes, et al.
Antimicrobial Agents and Chemotherapy|March 22, 2023
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzaeSujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, et al.
Pageof 25